EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency

Chiara Rodaro, Gianluca Tamaro, Elena Faleschini, Gianluca Tornese

Annals of Pediatric Endocrinology & Metabolism · 30.04.2025 · 30 (2) · 106-110

DOI: 10.6065/apem.2448202.101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pediatric Endocrinology & Metabolism, erschienen am 30.04.2025. Verfasst von Chiara Rodaro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Trieste, Trieste, Italy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health, Institute for Maternal and Child Health IRCCS Burlo Garofolo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy. Traditional rhGH treatments, although effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life. LAGHs have demonstrated non-inferiority to daily rhGHs in phase 3 clinical trials, showing similar efficacy in terms of growth velocity and safety profiles. Despite these advantages, concerns remain regarding the altered pharmacodynamics of LAGHs such as the lack of pulsatile secretion and potential for antibody formation. Although the overall safety of LAGHs has been confirmed, side effects, such as lipoatrophy at the injection site, may occur, especially with PEGylated formulations. Guidelines for prescribing LAGHs are currently evolving. LAGHs are not yet approved for other conditions traditionally treated with rhGHs, such as Turner or Noonan syndrome. Pediatric endocrinologists should carefully consider which patient groups would benefit most from this therapy, particularly individuals at risk of poor adherence to daily injections such as patients undergoing multidrug therapy, patients with needle phobia or behavioral disorders, very young children, adolescents, patients with separated parents, families that travel frequently, or children involved in activities such as scouting. LAGHs present an opportunity to enhance therapeutic outcomes and adherence, but careful patient selection remains critical to maximize their potential benefits.

Schlagwörter

Stichwörter der Autor:innen

ChildDwarfismGrowth hormoneHumansHypopituitarismPatient selectionPituitary

Autor:innen und Institutionen

  • Department of Medical Sciences, University of Trieste, Trieste, Italy.
  • Institute for Maternal and Child Health IRCCS "Burlo Garofolo", Trieste, Italy.

Förderung

  • Italian Ministry of Health
  • Institute for Maternal and Child Health IRCCS Burlo Garofolo

Zitieren

APA

Rodaro, C., Tamaro, G., Faleschini, E., & Tornese, G. (2025). Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency. Annals of Pediatric Endocrinology & Metabolism, 30(2), 106-110. https://doi.org/10.6065/apem.2448202.101

Vancouver

Rodaro C, Tamaro G, Faleschini E, Tornese G. Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency. Annals of Pediatric Endocrinology & Metabolism. 2025;30(2):106-110. doi:10.6065/apem.2448202.101

BibTeX
@article{Rodaro2025,
  author = {Rodaro, Chiara and Tamaro, Gianluca and Faleschini, Elena and Tornese, Gianluca},
  title = {Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency},
  journal = {Annals of Pediatric Endocrinology & Metabolism},
  year = {2025},
  volume = {30},
  number = {2},
  pages = {106--110},
  doi = {10.6065/apem.2448202.101}
}
Kostenlos starten →